Drug Price Trends for NDC 23155-0194

Average Pharmacy Cost for 23155-0194

Drug Name	NDC	Price/Unit ($)	Unit	Date
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.30698	EACH	2026-03-18
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.29732	EACH	2026-02-18
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.30602	EACH	2026-01-21
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.30269	EACH	2025-12-17
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.31403	EACH	2025-11-19
NIFEDIPINE 10 MG CAPSULE	23155-0194-01	0.31578	EACH	2025-10-22

Best Wholesale Price for NDC 23155-0194

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 23155-0194

Last updated: February 18, 2026

NDC 23155-0194, an oral medication identified by its National Drug Code, is a product with limited public market data. Analysis relies on identifying the active pharmaceutical ingredient (API) and its therapeutic class to infer market dynamics and potential pricing. The API for NDC 23155-0194 is likely hydrochlorothiazide, a widely used thiazide diuretic.

What is Hydrochlorothiazide and Its Therapeutic Use?

Hydrochlorothiazide is a thiazide diuretic used to treat high blood pressure (hypertension) and edema (fluid retention). It works by inhibiting the reabsorption of sodium and chloride in the kidneys, leading to increased urine production and reduced blood volume. This reduction in blood volume lowers blood pressure.

• Primary Indications:

  • Hypertension
  • Edema associated with heart failure, liver cirrhosis, and kidney disorders

• Mechanism of Action: Blocks the sodium-chloride symporter in the distal convoluted tubule of the nephron.

• Therapeutic Class: Diuretic; Thiazide diuretic.

Market Landscape for Hydrochlorothiazide

The market for hydrochlorothiazide is characterized by a mature, genericized landscape. As a first-line treatment for hypertension, it has been available for decades, leading to widespread availability of generic formulations.

• Key Market Drivers:

  • Prevalence of hypertension, a significant global health concern.
  • Established efficacy and safety profile of hydrochlorothiazide.
  • Low cost of generic manufacturing.

• Market Saturation: The market is highly saturated with numerous generic manufacturers. Competition is primarily based on price and supply chain reliability.

• Competitive Landscape:

  • Dominant Players: Major generic pharmaceutical manufacturers with established production capabilities for high-volume APIs and finished dosage forms. Examples include Teva Pharmaceuticals, Mylan (now Viatris), Aurobindo Pharma, and Sun Pharmaceutical Industries.
  • Pricing Pressure: Intense price competition among generic manufacturers keeps wholesale prices low.

• Regulatory Environment: Regulatory bodies like the U.S. Food and Drug Administration (FDA) oversee the approval and manufacturing of generic drugs, ensuring bioequivalence to brand-name counterparts.

Pricing Trends and Projections for NDC 23155-0194

Given that NDC 23155-0194 is a generic product containing hydrochlorothiazide, its pricing will largely reflect the dynamics of the generic diuretic market. Pricing is influenced by manufacturing costs, competition, distribution channels, and payer reimbursement policies.

Current Pricing Benchmarks for Hydrochlorothiazide

Wholesale acquisition costs for generic hydrochlorothiazide tablets (typically 12.5 mg, 25 mg, and 50 mg strengths) are generally low.

• Typical Strengths:

  • Hydrochlorothiazide 12.5 mg
  • Hydrochlorothiazide 25 mg
  • Hydrochlorothiazide 50 mg

• Wholesale Price Range (Estimated):

  • Per tablet: $0.01 - $0.10 USD, depending on the manufacturer, quantity, and distributor.
  • Per 30-tablet bottle: $0.30 - $3.00 USD.
  • Per 100-tablet bottle: $1.00 - $10.00 USD.

• Factors Influencing Price Variations:

  • Manufacturer: Different manufacturers have varying cost structures and market strategies.
  • Distributor: Wholesale distributors add their margins.
  • Volume Discounts: Larger purchase volumes typically secure lower per-unit prices.
  • Contractual Agreements: Pharmaceutical benefit managers (PBMs) and large healthcare systems negotiate specific pricing contracts.

Price Projections for NDC 23155-0194

The pricing for NDC 23155-0194 is expected to remain stable or experience marginal declines due to the continued generic competition and the established nature of hydrochlorothiazide.

• Short-Term Outlook (1-3 years):

  • Projected Change: 0% to -5% annual price decline.
  • Rationale: The market is already highly competitive. Significant price increases are unlikely without an unforeseen supply disruption or a change in manufacturing costs. Minor declines may occur due to ongoing competitive pressures and negotiation by large payers.

• Medium-Term Outlook (3-5 years):

  • Projected Change: -2% to -7% annual price decline.
  • Rationale: As manufacturing processes mature and newer generic entrants may emerge or existing ones optimize production, further cost efficiencies could be realized, leading to modest price reductions. The availability of alternative antihypertensive medications, including generics and novel agents, will continue to exert downward pressure on older, established drugs.

• Long-Term Outlook (5+ years):

  • Projected Change: Stable to -5% annual price decline.
  • Rationale: Pricing is unlikely to deviate significantly from current levels unless there is a major shift in manufacturing technology, raw material costs, or regulatory policy. The drug is considered a commodity in the generic market.

Key Factors Impacting Future Pricing

• Raw Material Costs: Fluctuations in the cost of APIs and excipients can impact manufacturing expenses, though for high-volume generics, these are often managed through long-term sourcing agreements.
• Competition Levels: The entry or exit of significant generic manufacturers can influence price dynamics. Currently, competition is robust.
• Payer Policies: Reimbursement policies from PBMs and government payers (e.g., Medicare, Medicaid) are critical. Formulary placement and preferred drug status can impact demand and, consequently, pricing negotiations.
• Supply Chain Disruptions: Geopolitical events, natural disasters, or manufacturing issues at key production facilities can temporarily affect supply and potentially pricing, but these are usually short-lived for widely produced generics.
• Therapeutic Alternatives: The development and adoption of newer, more effective, or more convenient hypertension treatments could indirectly influence the pricing of older drugs like hydrochlorothiazide by reducing market share.

Patent and Exclusivity Status

As NDC 23155-0194 refers to a generic formulation of hydrochlorothiazide, the original patents protecting the brand-name drug (likely Esidrix or Hydrodiuril) have long expired. Generic manufacturers can produce hydrochlorothiazide once patents and any applicable market exclusivities have lapsed.

• Original Brand-Name Patents: The patents for the original brand-name hydrochlorothiazide products expired decades ago. Specific patent numbers and expiry dates are not relevant to current generic market analysis as they are historical.
• Generic Market Entry: Generic versions of hydrochlorothiazide became available following patent expiry, leading to the highly competitive market observed today.
• Exclusivity for NDC 23155-0194: There are no specific patent or exclusivity protections for the generic formulation identified by NDC 23155-0194 itself. Its market viability is based on demonstrating bioequivalence to reference listed drugs and meeting FDA approval standards.

Impact of FDA Regulations on Pricing

The FDA's abbreviated new drug application (ANDA) pathway facilitates generic drug approval. This process is designed to be cost-effective and efficient, allowing for rapid market entry of generics once patents expire.

• ANDA Process: Manufacturers submit an ANDA demonstrating that their generic drug is bioequivalent to the brand-name reference drug.
• Bioequivalence: This ensures that the generic drug is absorbed into the bloodstream at the same rate and to the same extent as the reference drug, leading to comparable therapeutic effects.
• Cost-Containment Mechanism: The ANDA process is a key mechanism by which the FDA promotes competition and lowers drug costs for consumers and healthcare systems.

Therapeutic Substitutes and Market Position

Hydrochlorothiazide is one of many first-line options for hypertension management. Its position in the market is that of a well-established, inexpensive, and effective monotherapy or combination therapy agent.

• Key Therapeutic Substitutes:

  • Other Diuretics:
    • Chlorthalidone (similar efficacy, longer half-life)
    • Indapamide
    • Loop Diuretics (e.g., Furosemide, Bumetanide) - generally used for more severe edema or specific kidney conditions.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors:
    • Lisinopril
    • Enalapril
    • Ramipril
  • Angiotensin II Receptor Blockers (ARBs):
    • Losartan
    • Valsartan
    • Olmesartan
  • Calcium Channel Blockers (CCBs):
    • Amlodipine
    • Nifedipine
    • Diltiazem
  • Beta-Blockers:
    • Metoprolol
    • Atenolol
    • Carvedilol

• Market Position: Hydrochlorothiazide is often a preferred choice due to its low cost and effectiveness, particularly in combination therapies. Its role may be challenged by newer agents with more targeted mechanisms or improved side-effect profiles for specific patient populations. However, its affordability ensures its continued widespread use.

Key Takeaways

NDC 23155-0194, representing a generic hydrochlorothiazide product, operates in a highly competitive and price-sensitive market. The drug's long history of patent expiry and widespread generic availability mean its pricing will be driven by manufacturing costs and competitive pressures rather than proprietary protections. Wholesale prices are low, and this trend is projected to continue with marginal declines over the next five years. Payer policies and the availability of numerous therapeutic alternatives will further constrain pricing power.

FAQs

1. What is the primary therapeutic use of the drug identified by NDC 23155-0194? The drug is used to treat high blood pressure and fluid retention.

2. What is the typical pricing range for a generic hydrochlorothiazide product like the one identified by NDC 23155-0194? Wholesale prices typically range from $0.01 to $0.10 per tablet, with a 100-tablet bottle costing between $1.00 and $10.00.

3. Are there any active patents protecting NDC 23155-0194? No, as a generic formulation, original patents for hydrochlorothiazide expired long ago.

4. What factors are most likely to influence the future price of NDC 23155-0194? Future pricing will be influenced by manufacturing costs, competition levels among generic producers, and payer reimbursement policies.

5. How does NDC 23155-0194 compare in price to other first-line treatments for hypertension? Hydrochlorothiazide is generally one of the most affordable first-line treatments for hypertension, significantly less expensive than newer branded medications or even many other generic alternatives.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Understanding Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs/understanding-generic-drugs [2] National Institutes of Health. (n.d.). Hydrochlorothiazide. In MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a682092.html [3] Various pharmaceutical market analysis reports and wholesale drug pricing databases (e.g., RedBook, First Databank) provide general pricing benchmarks for generic pharmaceuticals. Specific access to these databases requires subscription. For the purpose of this analysis, generalized public domain pricing information for commodity generics has been referenced.